UNSPSC 51384605: Benzydamine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H23N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O21U048EF, chemically known as 1-propanamine, n,n-dimethyl-3-((1-(phenylmethyl)-1h-indazol-3-yl)oxy)- but generally known as benzydamine, which bears US NIH Compound Identifier 12555. Benzydamine most often comes in base, hydrochloride, n-oxide, and salicylate forms.

UNSPSC 51384605 Benzydamine is a Commodity code that nominally describes a specific anti-inflammatory pharmaceutical ingredient, but recent state and local solicitations tagged under this code show minimal alignment with that definition. Instead, the code appears in solicitations for broader pharmaceutical procurement — including naloxone (an opioid antagonist unrelated to benzydamine), generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local governments are using this code to solicit pharmaceutical products and pharmacy benefit management services, though the tagging suggests either inconsistent classification practices or the code's use as a catch-all within pharmaceutical commodity procurement. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). Work solicited ranges from competitive bids for naloxone and drug deactivation systems to requests for information on direct contracting relationships between state pharmacy programs and pharmaceutical manufacturers, to formal RFPs for generic pharmaceutical supply contracts distributed through authorized wholesalers.

Geographic activity centers on Florida, Texas, and the upper Midwest (Minnesota and Oregon), with the cooperative purchasing vehicle extending reach across multiple jurisdictions. Representative recent opportunities include Seminole County's IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's Request for Information (HHS0017013, due April 3, 2026) exploring vendor capabilities for a therapeutic pharmacy initiative direct-to-manufacturer program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products for state and local government facilities. The MMCAP procurement requires vendors to work through three authorized wholesalers and emphasizes price competitiveness (weighted at 75 percent), cGMP and Drug Supply Chain Security Act compliance, and participation in multi-state cooperative purchasing frameworks. The Seminole County solicitation includes potential FEMA funding and requires E-Verify compliance and specific insurance coverage; the Texas RFI functions as preliminary market intelligence rather than a formal competitive award.